An important role of interleukin-10 in counteracting excessive immune response in HT-29 cells exposed to Clostridium butyricum
© Gao et al.; licensee BioMed Central Ltd. 2012
Received: 1 November 2011
Accepted: 8 June 2012
Published: 8 June 2012
Clostridium butyricum has become increasingly important in preventing and treating intestinal inflammation. In the intestine it may increase the resistance of the gut to pathogen invasion via inducing the secretion of anti-inflammatory cytokines. Interleukin 10 (IL-10) plays a central role in preventing certain inflammatory diseases by down-regulating inflammatory cascades. In a previous study, we observed that the level of IL-10 mRNA was modulated by C. butyricum. The aim of this study was to investigate whether C. butyricum achieves its beneficial effects through IL-10.
We treated HT-29 cells with anti-IL-10 (IL-10 antibody) or siIL-10 (IL-10 small interfering RNA) to disrupt IL-10. In both cases, the effects of C. butyricum-induced NF-κB activation and IL-8 expression were enhanced. We also found that neutralization or knockdown of IL-10 could induce apoptosis and necrosis of HT-29 cells treated with C. butyricum compared with control cells.
These findings show that IL-10 serves an important role in C. butyricum-mediated immune protection, and in host recognition of C. butyricum.
Probiotic bacteria are live microorganisms which are beneficial to the host organism, and can exert health benefits beyond those of inherent basic nutrition. A recent study indicates that the use of probiotics is rapidly advancing from the field of nutrition towards therapeutic applications . Probiotics have proven useful in preventing and treating diarrhea. Crohn’s disease and ulcerative colitis patients exhibit loss of immune tolerance to enteric bacteria. Probiotics have modest but consistent prophylactic efficacy and can regulate innate and adaptive immunity to enhance innate defenses against microbes and maintainimmune homeostasis [2, 3]. Therefore, immune modulation and inhibition of excessive immune response and inflammation are proposed to be mechanisms of action of probiotics [4, 5].
It has been demonstrated that IL-10 plays a crucial role in down-regulating inflammatory cascades by suppressing the secretion of pro-inflammatory cytokines. IL-10-deficient mice develop chronic intestinal inflammation, which is in part caused by a loss of suppression of the mucosal immune response toward normal intestinal bacteria . Recent studies have reported that topical treatment with IL-10 is effective in preventing certain inflammatory diseases. Moreover, probiotics can exert a therapeutic effect mediated through an IL-10-dependent mechanism . It has been shown that oral administration of probiotics can prevent inflammation and mucosal ulcerations, which are associated with up-regulation of IL-10, which inhibits the increase of the CD4+ helper T cell population and down-regulates inflammatory cytokines .
Probiotics can exert immunomodulatory activities by increasing IL-10 production, which can in turn help prevent an excessive immune response. However, probiotic bacteria have multiple and diverse effects in the host, and not all probiotic strains act in this manner. The C. butyricum MIYAIRI II 588 stain has been used to prevent disturbances of microflora, treat diarrhea and enhance the humoral immune response in the human intestine . However, the mechanisms by which C. butyricum treats and prevents diarrhea remain unclear. The aim of the present study was to assess whether C. butyricum achieves its beneficial effects via modulation of IL-10 production.
Bacterial strains and culture conditions
C. butyricum MIYAIRI II 588 used in this study was obtained from Miyarisan Pharmaceutical Co. Ltd, Tokyo, Japan. This strain is a butyric-acid producing, spore-forming and gram-positive rod bacterium . It was cultured in MRS broth at 28°C in an anaerobic environment.
HT-29 human colonic epithelial cells were purchased from the cell bank of the type culture collection of the Chinese academy of sciences (Shanghai). Enterocyte-like HT-29 cells were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 100 U ml−1 penicillin, and 100 μg ml−1 streptomycin at 37°C in a humidified atmosphere of 5% CO2.
SiRNA transient transfection
One day before transfection, HT-29 cells (1 × 106 cells well−1) were allowed to attach and grow in 6-well culture plates (Corning, USA). When the plated cells in medium without antibiotics were 30–50% confluent, IL-10-specific siRNA (small interfering RNA) synthesized by Ribobio (Guangzhou, China) was transfected into cells with Lipofectamine 2000 (Invitrogen). After 48 h, cells were treated with C. butyricum and assayed for transfection efficiency by real-time PCR.
IL-10 antibody-blocking was performed as described previously . To prevent the effects of IL-10, supernatants were treated with IL-10 antibody (5 μg ml−1; HuaAn, China). These treated cells were then cultured in 6-well plates at 1 × 106 cell well−1. After 48 h, the cells were stimulated with C. butyricum.
Stimulation of cells
Before stimulation assays, the bacteria were collected and re-suspended in antibiotic-free 1640 media. To investigate whether C. butyricum regulates IL-10 expression in HT-29 cells, the cells were exposed to 1 × 106, 1 × 107, 1 × 108 CFU ml−1 of C. butyricum for 2 h. The culture media were collected and analyzed for IL-10 by an enzyme-linked immunosorbent assay (ELISA), and the same cells from the original culture medium were harvested for real-time PCR analysis.
HT-29 cells pretreated with IL-10 antibody or siIL-10 were treated with 2 ml 1640 media or C. butyricum suspensions at designated concentration (1 × 108 CFU ml−1), and incubated for 2 h. The culture media were collected and analyzed for IL-8 and IL-10 by ELISA, and the same cells from the original culture medium were harvested for real-time PCR and western blot analysis. In addition, we also detected the morphology of apoptotic cell nuclei using the PI method.
Determination of IL-8 secretion using a sandwich ELISA
Human IL-8 proteins were assayed using BlueGene ELISA Kits, according to the manufacturer’s instructions (BlueGene Biotechnology, Shanghai, China).
Western blot analysis for NF-κB (p50/105) and IκB expression
Total cellular and nuclear proteins were extracted according to the instructions of the nuclear and cytoplasmic protein extraction kit (Beyotime, Haimen, China). The nuclear extracts were used to determine NF-κB protein levels and the cytoplasmic extracts were used to determine IκB levels. The protein content of the lysates was estimated using an enhanced BCA protein assay kit (according to the manufacturer’s instructions). Fifty micrograms of protein from each sample were subjected to SDS-PAGE. After electrophoresis, proteins were electro-blotted to a Hybond-C Extra nitrocellulose membrane (Amersham, USA). The membrane was blocked at room temperature with 5% non-fat dry milk in TBS containing 0.3% Tween (TBS-T). The membrane was washed thrice with TBS-T and incubated overnight at 4°C with the primary antibody, anti-NF-κB (1:2000), anti-IκB (1:2500) and anti-β-actin (1:3000). This was followed by 1 h incubation with a 1:5000 dilution of the appropriate horseradish-peroxidase-conjugated secondary antibody. After incubation, the membrane was washed with TBS-T thrice. The antigen-antibody complexes were visualized by enhanced chemiluminescence and exposed to X-ray film for between 0.5 and 30 min .
Real-time quantitative PCR
Oligonucleotide primers used to amplify RNA transcripts
Forward primer (5′ to 3′)
Reverse primer (5′ to 3′)
CTA CAA TGA GCT GCG TGT GG
TAG CTC TTC TCC AGG GAG GA
ATG ACT TCC AAG CTG GCC GTG GCT
TCT CAG CCC TCT TCA AAA ACT TCT C
ATG CCC CAA GCT GAG AAC CAA GAC CCA
TCT CAA GGG GCT GGG TCA GCT ATC CCA
Propidium Iodide (PI) assay
Morphology of apoptotic cell nuclei was detected by staining with the DNA binding fluorochrome PI (Beyotime Institute of Biotechnology, Jiangsu, China). The nuclei of apoptotic and necrosis cells were observed using fluorescence microscopy .
Caspase-3 activity assay
The activity of caspase-3 was determined using the Caspase-3 activity Kit (Beyotime Institute of Biotechnology, Jiangsu, China). Cell lysates were prepared by incubating 2 × 106 cells ml−1 in extraction buffer for 15 min on ice. After centrifugation at 20,000 × g for 15 min at 4°C, the supernatants were collected. In a 100 μl reaction volume, 10 μl sample or buffer (blank) were incubated with the substrate Ac-DEVD-pNA (acetyl-Asp-Glu-Val-Asp p-nitroanilide) in a 96-well microplate for 2 h at 37°C. The optical absorbance was measured at 405 nm using a microplate reader (A-5082, TECAN, Austria). Caspase-3 activity was expressed as the percentage of enzyme activity compared with the control .
DNA fragmentation analysis
DNA was extracted using a DNA ladder extraction kit with spin column (Beyotime Institute of Biotechnology, Jiangsu, China). 10 μl of the DNA sample was separated on a 1.0% agarose gel and the DNA band pattern was visualized .
All statistical analyses were performed using Statistical Analysis System software (SAS V8). All results are shown as the average of more than three replicates. Data are presented as mean ± the standard error (SE). Duncan’s multiple range tests were used to evaluate the statistical significance of the results. Differences with p values of < 0.05 were considered significant.
C. butyricum stimulates elevated levels of IL-10 in HT-29 cells
Neutralization of IL-10 released by HT-29 cells enhances the effects of C. butyricum-induced NF-κB activation and IL-8 expression
Knockdown of IL-10 enhances the effects of C. butyricum-induced NF-κB activation and IL-8 expression
Disruption of IL-10 induces apoptosis and necrosis of HT-29 cells with C. butyricum
The intestinal epithelial cell surface represents the largest exposed surface of the body that must be protected by the immune system against toxic substance and pathogenic bacteria. All intestinal epithelial cells are usually capable of regulating the immune response through different mechanisms, one of which is the secretion of anti-inflammatory cytokines. Throughout the present study, we have focused on the role of IL-10 in regulating epithelial cell function. IL-10 is a potent inhibitor of pro-inflammatory cytokine production, and has been shown to inhibit production of IL-6 and IL-1β in macrophages [18, 19]. Supporting evidence for a role for IL-10 in inflammation is derived from studies in mice deficient in IL-10 or harboring mutated IL-10, which are a model of enterocolitis . These IL-10−/− mice under normal conditions show increased inflammatory responses and develop inflammatory bowel disease. Moreover, these IL-10−/− mice are extremely susceptible to infection-induced immunopathology . All these data suggest that endogenous IL-10 synthesis plays an important role in vivo in down-regulating immune responses and preventing host immunopathology. Moreover, beneficial effects in colitis patients have been obtained via probiotic bacteria-induced IL-10 production .
In our current study, C. butyricum stimulates elevated levels of IL-10 in HT-29 cells. Because this probiotic strain is frequently used in the management of allergic diseases or gastroenteritis, it is hypothesized that it promotes mucosal tolerance mediated through IL-10. Therefore, we further assessed the role of IL-10 in probiotic-mediated immune modulation by neutralizing or knocking down IL-10 in HT-29 cells. It was found that disruption of IL-10 enhanced effects of C. butyricum-induced NF-κB activation and IL-8 secretion. The results demonstrate that C. butyricum modifies the mucosal immune response to modulate the levels of specific molecules such as cytokines by increasing IL-10 levels and consequently decreasing inflammatory cytokines.
The viability of cells is dependent on cytokines. However, high-dose cytokines can induce apoptosis and necrosis. Bacteria and their metabolites can induce an anti-proliferative effect through induction of apoptosis [23–25]. In the current study, disruption of IL-10 enhanced C. butyricum-induced IL-8 secretion. We further assessed whether this probiotic strain induced apoptosis and necrosis of HT-29 cells due to a lack of effect of IL-10. The results showed that the number of abnormal cells significantly increased compared to the control, indicating that disruption of IL-10 caused a loss of suppression of the mucosal immune response and even excessive apoptosis and necrosis. This study confirmed that C. butyricum exerts anti-inflammatory effects and enhances tolerance to bacteria through increasing IL-10 production. Moreover, some subsets of Crohn’s disease patients are actually deficient in the production of IL-10, and therefore in this subset this probiotic therapy may be of limited use.
The adaptive co-evolution of humans and bacteria has resulted in the establishment of commensal relationships where neither partner is disadvantaged, or symbiotic relationships where both partners benefit . In our current study, intestinal epithelial cells can secrete IL-10 to down-regulate inflammatory cascades through suppressing the secretion of pro-inflammatory cytokines. On the other hand, C. butyricum can drive the secretion of IL-10 to enhance tolerance to bacteria. Such mechanisms allow the host to recognize symbiotic bacteria without eliciting a deleterious immune response, and enable the symbiotic bacteria to reside in the gut, thus providing unique metabolic traits or other benefits. This pathway may be part of an evolutionarily primitive form of adaptive immunity.
When HT-29 cells were pretreated with anti-IL-10 or siIL-10, C. butyricum induced an excessive immune response and even apoptosis and necrosis compared with control cells. These findings show that C. butyricum achieves its beneficial effects on immune modulation through IL-10. On the other hand, C. butyricum may have limited usefulness when the host is deficient in the production of IL-10; this requires further clarification.
This work was supported by the National Natural Science Foundation of China (Grant No. 30901039) and the Ningbo City Bureau of Science and Technology (Grant No. 2009A610155).
- Jia W, Li H, Zhao L, Nicholson JK: Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov. 2008, 7: 123-129.PubMedView ArticleGoogle Scholar
- Haller D, Bode C, Hammes WP, Pfeifer AM, Schiffrin EJ, Blum S: Nonpathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut. 2000, 47: 79-87.PubMedPubMed CentralView ArticleGoogle Scholar
- McCracken VJ, Chun T, Baldeon ME, Ahrne S, Molin G, Mackie RI, Gaskins HR: TNF-alpha sensitizes HT-29 colonic epithelial cells to intestinal lactobacilli. Exp Biol Med. 2002, 227: 665-670.Google Scholar
- Shanahan F: Probiotics in inflammatory bowel disease - therapeutic rationale and role. Adv Drug Deliv Rev. 2004, 56: 809-818.PubMedView ArticleGoogle Scholar
- Sartor RB: Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when. Curr Opin Gastroenterol. 2003, 19: 358-365.PubMedView ArticleGoogle Scholar
- Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W: Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993, 75 (2): 263-274.PubMedView ArticleGoogle Scholar
- Lavasani S, Dzhambazov B, Nouri M, Fåk F, Buske S, Molin G, Thorlacius H, Alenfall J, Jeppsson B, Weström B: A novel Probiotic mixture exerts a therapeutic effect on experimental autoimmuneencephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS One. 2010, 5 (2): e9009-PubMedPubMed CentralView ArticleGoogle Scholar
- Mengheri E: Health, probiotics, and inflammation. J Clin Gastroenterol. 2008, 42: s177-s178.PubMedView ArticleGoogle Scholar
- Ito I, Hayashi T, Iguchi A, Endo H, Nakao M, Kato S, Nabeshima T, Ogura Y: Effects of administration of Clostridium butyricum to patients receiving long-term tube feeding. Jpn J Geriat. 1997, 34: 298-304.View ArticleGoogle Scholar
- Pan X, Wu T, Zhang L, Song Z, Tang H, Zhao Z: In vitro evaluation on adherence and antimicrobial properties of a candidate probiotic Clostridium butyricum CB2 for farmed fish. J Appl Microbiol. 2008, 105: 1623-1629.PubMedView ArticleGoogle Scholar
- Li YY, Chang JW, Hsieh LL, Yeh KY: Neutralization of interleukin (IL)-10 released by monocytes/macrophages enhances the up-regulatory effect of monocyte/macrophage-derived IL-6 on expressions of IL-6 and MUC1, and migration in HT-29 colon cancer cells. Cell Immunol. 2010, 265 (2): 164-171.PubMedView ArticleGoogle Scholar
- Wang JB, Qi LL, Zheng SD, Wang HZ, Wu TX: Curcumin suppresses PPARδ expression and related genes in HT-29 cells. World J Gastroenterol. 2009, 15: 1346-1352.PubMedPubMed CentralView ArticleGoogle Scholar
- Jin S, Zhang QY, Kang XM, Wang JX, Zhao WH: Daidzein induces MCF-7 breast cancer cell apoptosis via the mitochondrial pathway. Ann Oncol. 2010, 21: 263-268.PubMedView ArticleGoogle Scholar
- Jia YD, Lin JX, Mi YL, Zhang CQ: Quercetin attenuates cadmium-induced oxidative damage and apoptosis in granulosa cells from chicken ovarian follicles. Reprod Toxicol. 2011, 31 (4): 477-485.PubMedView ArticleGoogle Scholar
- Christensen HR, Frøkiaer H, Pestka JJ: Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J Immunol. 2002, 168 (1): 171-178.PubMedView ArticleGoogle Scholar
- Altonsy MO, Andrews SC, Tuohy KM: Differential induction of apoptosis in human colonic carcinoma cells (Caco-2) by Atopobium, and commensal, probiotic and enteropathogenic bacteria: mediation by the mitochondrial pathway. Int J Food Microbiol. 2010, 137 (2–3): 190-203.PubMedView ArticleGoogle Scholar
- Zhang WJ, Li BH, Yang XZ, Li PD, Yuan Q, Liu XH, Xu SB, Zhang Y, Yuan J, Gerhard GS, Masker KK, Dong C, Koltun WA, Chorney MJ: IL-4-induced Stat6 activities affect apoptosis and gene expression in breast cancer cells. Cytokine. 2008, 42 (1): 39-PubMedView ArticleGoogle Scholar
- Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O’Garra A: IL-10 inhibits cytokine production by activated macrophages. J Immunol. 1991, 147: 3815-3822.PubMedGoogle Scholar
- Poe JC, Wagner DH, Miller RW, Stout RD, Suttles J: IL-4 and IL-10 modulation of CD40-mediated signaling of monocyte IL-1b synthesis and rescue from apoptosis. J Immunol. 1997, 159: 846-852.PubMedGoogle Scholar
- Rennick DM, Fort MM: Lesson from genetically engineered animal models XII: IL-10- deficient mice and intestinal inflammation. Am J Physiol. 2000, 278: g829-g833.Google Scholar
- Gazzinelli RT, Wysocka M, Hieny S, Scharton-Kersten T, Cheever A, Kuhn R, Muller W, Trinchieri G, Sher A: In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-c and TNF-a. J Immunol. 1996, 157: 798-805.PubMedGoogle Scholar
- Akemi I, Tatsuichiro S, Kimitoshi K, Shigeaki M, Toshiki Ua, Satoshi Mo, Hiromi S, Taeko H, Yoshinori U: Anti-inflammatory activity of probiotic Bifidobacterium: enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells. World J Gastroenterol. 2008, 14 (16): 2511-2516.View ArticleGoogle Scholar
- Smits HH, Engering A, van der Kleij D, de Jong EC, Schipper K, van Capel TM, Zaat BA, Yazdanbakhsh M, Wierenga EA, van Kooyk Y, Kapsenberg ML: Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol. 2005, 115 (6): 1260-1267.PubMedView ArticleGoogle Scholar
- Kim SY, Kim JY, Kim SH, Bae HJ, Yi H, Yoon SH, Koo BS, Kwon M, Cho JY, Lee CE, Hong S: Surfactin from Bacillus subtilis displays antiproliferative effect via apoptosis induction, cell cycle arrest and survival signaling suppression. FEBS Lett. 2007, 581: 865-871.PubMedView ArticleGoogle Scholar
- Koonin EV, Aravind L: Origin and evolution of eukaryotic apoptosis: the bacterial connection. Cell Death Differ. 2002, 9: 394-404.PubMedView ArticleGoogle Scholar
- Hooper LV, Gordon JI: Commensal host-bacterial relationships in the gut. Science. 2001, 292: 1114-1118.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.